Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by nobody – 2019-04-05 08:37 (745 d 09:08 ago) – Posting: # 20124
Views: 2,470

» The fact that it is also a royal waste of money is of course only secondary.

Full-blown development mode. Accept it. Tell the sponsor you can't do the trial, if you are not qualified for PD-endpoint testing.

Kindest regards, nobody

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 6 (0 registered, 6 guests [including 2 identified bots]).
Forum time: Monday 17:45 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5